At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
CAR T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating CAR T cells for Multiple Myeloma. Currently recruiting, targeting 20 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedSep 2017
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionDec 2029
Study CompletionDec 2030
First PostedSep 5, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.8 years agoPrimary completion in 3.5 years
Arms & Interventions
Single armexperimental
CAR T cells to treat MM
Biological: CAR T cells
Interventions
CAR T cellsbiological
Infusion of multi-CAR T cells